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SUMMARY
Longitudinal cohort studies are important to describe the
dynamics of naturally acquired antibody response profiles to
defined Plasmodium falciparum malaria antigens relative to
clinical malaria episodes. In children under 7 years of age in
The Gambia, serum IgG responses were measured to P. falci-
parum merozoite antigens AMA1, EBA175, MSP119, MSP2
and crude schizont extract, over a 10-month period. Persis-
tence of antibody responses was measured in 152 children dur-
ing the dry season when there was virtually no malaria
transmission, and 103 children were monitored for new
episodes of clinical malaria during the subsequent wet season
when transmission occurred. Children who experienced clini-
cal malaria had lower antibody levels at the start of the study
than those who remained free from malaria. Associations
between dry season antibody persistence and subsequent wet
season antibody levels suggested robust immunological
memory responses. Mean antibody levels to all antigens were
elevated by the end of the wet season in children who experi-
enced clinical malaria; each of these children had a boosted
antibody response to at least one antigen. In all children,
antibody avidities were lower against MSP2 than other
antigens, a difference that did not change throughout the study
period or in relation to clinical malaria episodes.
Keywords malaria, IgG, immunological memory, antibody
avidity, malarial vaccine, merozoite antigens
INTRODUCTION
Plasmodium falciparum infection remains a significant
cause of mortality among children in malaria endemic
countries. High antibody levels are generally associated
with subsequent reduced susceptibility to clinical malaria
(1–6). Antibody levels usually increase markedly within 1
or 2 weeks after the onset of symptoms when individuals
who have previously had malaria are exposed to a new
malaria infection (7–9). Although antibody levels normally
decline after an infection is resolved, the persistence of
moderate antibody levels is seen in a substantial propor-
tion of individuals, and this persistence has been shown to
increase with age among young children (10). Such persis-
tent antibody production might be a marker of humoral
immune memory capacity, but it is unknown whether this
correlates with the ability to make rapid boosted antibody
responses upon exposure to subsequent P. falciparum
infections. Studies of serum antibodies prior to, during,
and following clinical P. falciparum infections are impor-
tant to investigate this.
It has been proposed that recent episodes of clinical
malaria in humans are associated with lower antibody
avidities in comparison with individuals who have resolved
clinical infections, suggesting that higher antibody avidity
is associated with enhanced immunity to clinical infection
(11–13). Antibody avidity maturation was described in a
murine model of Plasmodium chabaudi infection, indicat-
ing increasing antibody avidities after primary and second-
ary infections, and continued increase after multiple
infections (14). One study suggests that increases in
antibody avidities occur during resolution of clinical
P. falciparum infection in humans, reflecting maturation of
antibody responses to P. falciparum (11), and another
indicates that high avidity antibodies are associated with
protection from clinical malaria (15).
This study takes advantage of the highly seasonal
pattern of malaria transmission in The Gambia, where
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dry season and high during the wet season, which leads to
highly seasonal incidence of clinical malaria. Naturally
acquired antibodies were examined at different time points
during a dry and subsequent wet season. The study cohort
of children up to 7 years of age in The Gambia was previ-
ously analysed for the determinants of persistence of anti-
body levels to several merozoite stage antigens during the
dry season (10). Here, antibody responses during the wet
season were analysed, including assay of antibody avidity.
The antibody response profiles were examined in relation
to individual episodes of clinical malaria, and for the
cohort as a whole over time including the preceding dry
season.
MATERIALS AND METHODS
Study area
In The Gambia, transmission of malaria occurs between
July and December, during and immediately following the
annual rainy season, with peak incidence of clinical
malaria normally between September and November (16).
All study subjects were living in The Gambia in the town
of Farafenni and surrounding villages. The studies were
reviewed and approved by the Medical Research Council
Scientific Coordinating Committee and the Medical
Research Council and Gambian Government Joint Ethics
Committee.
Dry and wet season cohort (February–December 2004)
In February and March 2004, parents or caregivers of 152
children under 74 months of age gave informed consent
for a community-based survey of infection and antibody
levels over a 12-week period. From each child, a venous
blood sample (5 mL) was collected at enrolment (day 0),
for serum and thick blood smear preparation, and finger
prick (300 lL) blood samples were requested every
2 weeks.
At the end of the 12-week dry season study, all partici-
pants were provided with bed-nets and deltamethrin insec-
ticide treatment for use throughout the subsequent wet
season. Approximately 1 month later, during the wet sea-
son, written informed consent was sought for participation
in a follow-up study of malaria and antibody responses.
A finger prick sample for serum and thick blood smear
preparation was collected early during the wet season in
July and at the end of the wet season in December. Chil-
dren were visited by field workers every week between
these two surveys, and if they had fever (axillary tempera-
ture ‡37Æ5 C) or reported history of fever within the previ-
ous 48 h, a finger prick blood sample was taken and
tested immediately for malaria using a rapid diagnostic
test (RDT – OptiMAL
 ; DiaMed, Dakar, Senegal). A
thick blood smear was taken for confirmatory laboratory
analysis, and the remaining volume was collected for
serum. If either the RDT or thick blood smear were P. fal-
ciparum positive, the therapy recommended in 2004 was
provided, consisting of oral chloroquine (10 mg⁄kg daily
for 3 days) with sulphadoxine-pyrimethamine (1⁄2 tablet
per 10 kg). After each clinical malaria episode, a follow-
up finger prick blood sample for serum and thick smear
was requested within 3 weeks of treatment.
Malaria parasite detection and serum preparation
Thick blood smears and RDTs were performed directly
from the finger prick samples. Giemsa-stained thick blood
smears were read by two experienced microscopists examin-
ing 100 high-powered fields (·1000 magnification) to deter-
mine the presence or absence of detectable P. falciparum.
Finger prick blood samples for antibody analysis were
collected in serum separator tubes (BD Vacutainer systems,
Oxford, UK) and stored on ice during transfer from the
field to the laboratory. On arrival at the laboratory, tubes
were centrifuged at 1100 g for 5 min, and sera removed for
storage at )80 C prior to use in antibody assays.
Parasite antigens
Recombinant proteins representing blood stage vaccine
candidate antigens, AMA1, EBA175, MSP119 and MSP2
(two allelic types) were used. The AMA1 antigen was the
full-length ectodomain, expressed in Escherichia coli, rep-
resenting amino acids 83–531 of the P. falciparum strain
3D7 AMA1 (17). The EBA175 protein was a baculovirus-
expressed 8His-tagged antigen representing amino acids
144–753 of the EBA175 sequence in the 3D7 strain, corre-
sponding to the cysteine-rich region II (18). Three E. coli-
expressed GST fusion proteins were used, one based on
the MSP119 sequence of the Wellcome P. falciparum strain
(19), and two based on MSP2 amino acids 1–184 and 22–
247 of the CH150⁄9 (type A) and Dd2 (type B) alleles
respectively (20). The GST fusion tag alone was also
expressed from the pGEX-2T vector as a negative control
antigen. P. falciparum parasites from the 3D7 parasite
clone were cultured to prepare schizont extract as crude
P. falciparum parasite antigen.
Antibody assays
Serum IgG antibody reactivities were measured by ELISA
absorbances (optical density, OD) at 490 nm, following
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96-well plates (Immulon 4 HBX, Dynatech, Fisher Scienti-
fic, Loughborough, UK) was coated with 50 ng recombi-
nant antigen, or 5 lg crude schizont extract antigen, in
100 lL coating buffer overnight at 4 C. Plate wells were
washed four times in 0Æ005% Tween20 (PBS⁄T), and
blocked for 4 h with 1% milk powder in PBS⁄T. Test sera
were added in duplicate at 1⁄500 dilution (in PBS⁄T with
1% milk powder), and incubated overnight at 4 C.
To assess antibody avidity, chaotropic anion dissociation
of antibody–antigen interactions with 100 lL guanidine
thiocyanate at 4, 3, 2, 1, 0Æ5 and 0Æ1 M concentrations was
used with a pool of positive control sera, collected from
nine adults from the Brefet region of The Gambia, who
had high ELISA OD antibody reactivities to all antigens
(22). A single concentration of 0Æ5 M guanidine, in dupli-
cate, was selected to examine relative antibody avidity for
test serum to antigens. This concentration of guanidine
was suitable to elute antibody within the log-linear phase
of the curve for all antigens, according to positive control
samples. Plates were incubated for 12–15 min at ambient
temperature before removal of guanidine by washing in
PBS⁄T. Wells were washed four times, then incubated for
3 h with 100 lL of horseradish peroxidase-conjugated
goat anti-human IgG (Dako UK, Ltd, Cambridgeshire,
UK) at 1⁄5000. After four further washes, 100 lL sub-
strate solution was added (0Æ4m g⁄mL o-Phenylenediamine
dihydrochloride, 0Æ1 M citric acid, 0Æ2 M Na2HPO4), and
incubated for 15 min before adding 50 lL2 M sulphuric
acid and determining OD at 490 nm. To generate relative
antibody avidity indices for test sera, the ratio of ELISAOD
for sera incubated in the presence of 0Æ5 M guanidine thiocy-
anate, and OD without guanidine incubation, were calcu-
lated for AMA1, MSP119, MSP2A and MSP2B antigens.
Statistical analysis
Estimates of the persistence of dry season antibody
responses were made previously for children with samples
at five or more time points, from day 0 until the end of
the 12-week dry season study period. Dry season ELISA
absorbance OD values were transformed into standardized
units using a standard curve. For comparison with wet
season ELISA ODs, persistence of dry season antibody
response was determined by a single parameter: the lowest
antibody level estimated during the dry season as a pro-
portion of the antibody level at day 0 (10).
To examine differences in antibodies between groups,
the two sample t-test for parametric data or the Wilcoxon
rank sum (Mann–Whitney) test for nonparametric data
(on non-normally distributed data or data with unequal
variance between sample groups) was used. Linear regres-
sion was used to test associations between continuous
dependent and independent variables. For normally dis-
tributed data, unadjusted Pearson’s R
2 coefficient (slope
between x and y) and P values are reported. For non-nor-
mally distributed data, Spearman’s Rho, and P values are
reported. For children with clinical malaria, comparisons
were made between proportions with and without anti-
body increases >0Æ5 OD ELISA units to individual anti-
gens (0Æ5 ELISA OD represents a value greater than 3 SDs
above the mean negative control values for each antigen
and allows for comparisons between antigens).
RESULTS
Follow-up of the cohort and clinical episodes
Written informed consent was given for 152 children to
participate throughout the dry season study. Of this total,
138 participants completed the 12-week dry season survey,
and 124 children provided samples at five or more time
points from day 0 until the end of the dry season; these
samples were analysed for persistence of antibody response
(10). After appropriate additional informed consent, 118
of the children participated in the subsequent wet season
study. By the end of the wet season, there were 103 chil-
dren with samples available at three cross-sectional time
points: early during the dry season in February (day 0 for
each individual child), early in the wet season before malaria
incidence had increased (mean day 154, range 143–179), and
the end of the wet season (mean day 285, range 274–299).
P. falciparum parasites were detected in blood smears from
49 (48%) of the children early during the dry season, from
six (6%) of the children early during the wet season and
from 30 (29%) of the children at the end of the wet season.
In total, during the wet season, P. falciparum parasites were
detected in blood smears of 46 (45%) of the children.
Thirty four (33%) of the children were determined to
have experienced an episode of clinical malaria. These
children had parasite positive thick smear or RDT with
fever, or reported history of fever within the previous
48 h, and were treated for clinical infection. There were 21
children with an episode of clinical malaria from whom a
blood sample was collected at the time of diagnosis and
another sample collected within 18 days after the start of
treatment for clinical infection, allowing antibody profiles
to be examined in detail for these children (for the remain-
ing 13 children with an episode of clinical malaria, sam-
ples were not collected post-treatment).
The mean age of children at the start of the dry season
was 3Æ97 years (SD 1Æ53). There was no significant age dif-
ference between children who experienced an episode of
clinical malaria during the wet season (mean 4Æ27 years,
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1Æ52). The cohort was composed of 43 females and 60
males, and episodes of clinical malaria were not associated
with gender (female n = 14, male n = 20).
Antibody levels were boosted during the wet season
Mean serum antibody levels to all of the parasite blood
stage antigens increased during the wet season in children
who experienced an episode of clinical malaria, being sig-
nificantly higher at the end of season (day 285) than pre-
season (days 0 and 154, Figure 1a). Among those who did
not have an episode of clinical malaria, there was much
less evidence of boosting in the group as a whole. Mean
antibody levels at day 285 were lower than at day 0, and
they were only marginally higher than at day 154 (Fig-
ure 1b). However, there were antibody increases greater
than 0Æ5 ELISA OD units to one or more antigens in 24
(35%) of the children who did not have clinical malaria, as
well as in all of the children who had clinical malaria.
Although this cohort study was not statistically powered
to investigate whether antibody reactivities were associated
with protection from malaria, children who experienced
clinical malaria had lower initial (day 0) antibody levels
(mean ELISA OD = 0Æ805) to P. falciparum schizont
extract than children who remained free of clinical malaria
(mean ELISA OD = 1Æ013; P =0 Æ029). The trend was sim-
ilar for the individual recombinant antigens, although
these were not significant (Table 1).
Associations between dry and wet season antibodies
Longer persistence of antibodies during the dry season
was significantly associated with higher end of wet season
(mean day 285) antibody levels for all antigens except
MSP2 (Table 2). The data indicate that the elevated ability
to sustain antibody levels can persist throughout the dry
and wet seasons in young children. No differences in per-
sistence of dry season antibody response, or dry season
parasitaemia, were observed between children who had
clinical malaria during the subsequent wet season and
those who did not.
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Figure 1 Changes in mean antibody levels between early dry season (day 0), start of malaria transmission season (mean day 154) and end
of the malaria transmission season (mean day 285) for children with (a, n = 34) and without (b, n = 69) a recorded episode of clinical
malaria during the transmission season. Significant differences between days 0 and 285 or days 154 and 285 antibody levels are shown
(**P <0 Æ01, *P <0 Æ05).
Table 1 Comparison between mean (SD) antibody optical density
values at day 0 early in the dry season for children with and
without clinical malaria during the wet season
Antigen
No clinical
malaria
(n = 69)
Clinical
malaria
(n = 34) P-value
AMA1 1Æ39 (0Æ88) 1Æ24 (1Æ07) 0Æ48
EBA175 0Æ74 (0Æ81) 0Æ60 (0Æ92) 0Æ46
MSP119 1Æ18 (0Æ83) 0Æ95 (0Æ93) 0Æ21
MSP2A 0Æ67 (0Æ70) 0Æ59 (0Æ71) 0Æ57
MSP2B 0Æ95 (0Æ86) 0Æ88 (0Æ92) 0Æ71
Schizont extract 1Æ01 (0Æ44) 0Æ81 (0Æ46) 0Æ03
Table 2 Correlation co-efficient between dry season lowest
antibody concentrations as determined previously (10) and
antibody levels at the end of the following transmission season
(mean day 285)
Antigen R
2 P-value
AMA1 (n = 77) 0Æ06 0Æ03
EBA175 (n = 26) 0Æ33 <0Æ01
MSP119 (n = 69) 0Æ06 0Æ04
MSP2A (n = 42) 0Æ08 0Æ07
MSP2B (n = 60) 0Æ03 0Æ17
Schizont extract (n = 64) 0Æ08 0Æ03
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malaria
Very diverse longitudinal antibody profiles were observed
in children who experienced clinical malaria. Individual
antibody profiles are shown for 21 children who had clini-
cal malaria during the wet season and from whom a fol-
low-up sample was obtained within 18 days post-clinical
episode (Figure 2). Some children maintained elevated spe-
cific antibody levels throughout the dry and wet seasons
(LA004, LA102, LA117). Other children had low antibody
levels throughout both seasons until the time of clinical
malaria (LA051, LA101) or declining antibody levels dur-
ing the dry season and elevated levels at the time of clini-
cal malaria (LA095, LA136). Thus, children with highly
diverse longitudinal antibody profiles were vulnerable to
experience an episode of clinical malaria.
The individual profiles indicate that peak antibody lev-
els usually occurred during or immediately following clini-
cal infections. Such rapid responses co-incident with
malaria episodes suggest robust immune memory. Anti-
body levels were often reduced from peak levels by the
end of the wet season, but were generally higher than
those observed at the beginning of the wet season. Some
individuals (LA018, LA095, LA112, LA124) showed
increases in antibody levels to all antigens tested, whereas
others (LA034, LA101, LA125, LA89, LA112, LA124)
showed increases in antibody levels only to particular anti-
gens (Figure 2).
Figure 3 illustrates the occurrence of antibody increases
of >0Æ5 ELISA OD units among these 21 children during
the wet season. Throughout the wet season, antibody lev-
els against EBA175 remained <0Æ5 ELISA OD units in
seven (33%) of these 21 children, indicating limited boost-
ing of responses to EBA175 compared with other anti-
gens. Persistently low antibody levels of <0Æ5 ELISA OD
were seen in only three children for AMA1 and MSP2A,
in two children for MSP2B, and in only one child for
MSP119 and schizont extract (Figure 3). Despite the fre-
quent low reactivity to individual antigens, all children
with clinical malaria (n = 34) had increases of >0Æ5
ELISA OD in one or more of the antigens during the wet
season.
Lower antibody avidity measures for MSP2 antigens
than AMA1 or MSP119
The quality of antibody response was considered in terms
of antibody avidity to individual recombinant antigens for
samples with antibody levels >0Æ5 ELISA OD units. Avid-
ities were neither examined for schizont extract, as this is
a heterogeneous crude antigen preparation, nor for
EBA175, as relatively few children had high antibody lev-
els to this antigen.
At all time points, lower antibody avidities were
observed to both allelic forms of MSP2, compared with
MSP119 and AMA1 (Figure 4). The validity of exact com-
parisons between differing types of test antigen is uncer-
tain, but highest avidity indices were seen to MSP119
(0Æ8), followed by AMA1 (0Æ6) and avidity indices to
MSP2 antigens were markedly lower (0Æ1t o0 Æ2) (Fig-
ure 4). Avidity indices for a positive control pool of nine
sera from Gambian adults were higher (0Æ90 for AMA1,
0Æ94 for MSP119,0 Æ65 for MSP2A and 0Æ54 for MSP2B).
There were positive associations between antibody levels
and antibody avidity index at all time points for AMA1
(day 0: R
2 =0 Æ21, P <0 Æ001; day 154: R
2 =0 Æ26, P <
0Æ001; day 285: R
2 =0 Æ16, P =0 Æ001) and MSP119 (day 0:
R
2 =0 Æ11, P =0 Æ007; day 154: R
2 =0 Æ08, P =0 Æ048;
day 285: R
2 =0 Æ16, P =0 Æ001), but not for MSP2 anti-
gens. There were no consistent associations between anti-
body avidity measures and age or persistence of antibody
response. There were also no observed correlations between
antibody avidity and presence of parasite infection, or
occurrence of clinical malaria.
DISCUSSION
In this cohort study in The Gambia, increases in serum
IgG antibody levels to P. falciparum merozoite antigens
were observed in many children during the wet season
when malaria transmission occurred. Rapid increases
occurred around the time of clinical infection in all chil-
dren who had a clinical malaria episode for at least one
of the tested antigens, indicating memory responses that
were boosted during the infections. Following treatment
and resolution of clinical malaria, antibodies to specific
antigens can commonly be detected for months, although
the levels decline (7,8). A previous analysis of the dry sea-
son period in the Gambian cohort studied here showed
that elevated antibody levels can be maintained for
extended periods in some individuals even in the absence
of persistent infection, particularly in those older than
5 years of age (10). Children with more persistent dry sea-
son antibody responses also had higher antibody levels at
the end of the wet season, compared with children who
had more rapid dry season antibody decline. Antibody
levels to all antigens were higher at the end of the wet
season in those who had clinical malaria infections, but
these levels were sometimes lower than the peak levels
observed around the time of infection. All children with
clinical malaria had increases in antibody levels of one or
more antigens by the end of the wet season, whereas such
increases were only seen in approximately one-third of
O. J. Akpogheneta et al. Parasite Immunology
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Figure 2 Longitudinal antibody profiles for 21 children with an episode of clinical P. falciparum malaria during the transmission season
and a follow-up sample collected within 18 days post-treatment. An arrow indicates day of treatment for clinical malaria. Day 0 is early in
the dry season (February), and day 154 is at the beginning of the wet season (July) after which time most malaria transmission occurs.
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detected.
Rates of dry season antibody decline to P. falciparum
antigens in the absence of persistent infection were previ-
ously associated with age of children and differences
between malaria antigens (10). Antibody decline rates to
Pneumococcal capsular polysaccharide vaccines have also
varied among antigens tested (23). It is possible that the
rate of antibody decline may correlate with protective effi-
cacy, and although there was no association with risk of
malaria in the present study, this could be investigated in
a larger study.
Antibodies with low avidities are considered to be pro-
duced mainly as a result of non-germinal centre B cell
development, but excessive stimulation of B cells and
maintenance of large numbers of somatically mutated B
cells could also be associated with low avidity antibodies
in response to malaria antigens (24). Increasing antibody
avidities have been described to MSP1 and schizont
extract antigens following malaria infection (11,14), but
recent data also suggest that malaria infection can inhibit
affinity maturation of antibodies (25). Naturally acquired
antibody avidities to malaria antigens have not been previ-
ously investigated among young children, and interestingly
we found that these did not change between different sam-
pling periods in relation to seasonal malaria transmission.
Although high antibody levels were observed to MSP2,
antibody avidities to this antigen were constantly low, sug-
gesting that exposure to new infections did not boost avid-
ities to comparable levels with those for AMA1 or
MSP119 in this population. There is evidence that MSP2
antigens promote an IgG3 skewed antibody response com-
pared with other malaria antigens (26). While IgG3 anti-
bodies have a shorter half life than IgG1 antibodies, the
relative affinity of different antibody subclasses to malaria
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MSP2A and MSP2B in serum from children with antibody levels
>0Æ5 optical density (OD) at each time points. Relative antibody
avidity indices (ELISA OD with⁄ELISA OD without 0Æ5 m
guanidine thiocyanate incubation) during the dry season (day 0),
beginning of malaria transmission season (day 154) and end of
the malaria transmission season (day 285). AMA1 day 0: n = 74,
day 154: n = 55, day 285: n = 70; MSP119 day 0: n = 64, day 154:
n = 47, day 285: n = 61; MSP2A day 0: n = 44, day 154: n = 32,
day 285: n = 48; MSP2B day 0: n = 52, day154: n = 34, day 285:
n = 56.
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cine study showed no differences between antibody avid-
ities to AMA1 or MSP1 conformation-dependent and
conformation-independent epitopes (27; MSP2 could not
be compared as that antigen is not present in rodent
malaria parasites). Less persistent antibody responses were
observed to MSP2 than to AMA1, EBA175, MSP119 and
schizont extract antigens during the dry season amongst
children in this cohort (10). Taken together, these observa-
tions suggest that MSP2 may promote less mature anti-
body responses than those to other antigens such as
AMA1 and MSP119. It is unknown whether the differ-
ences in MSP2 antibody avidities observed in this study
relate to a particular structure of the MSP2 antigens
within the tandem repeat sequences, or the polymorphic
nature of some of these repeat sequences (28). Examina-
tion of antibody avidity in detail against reagents repre-
senting different parts of the MSP2 antigen would be
necessary to further investigate this.
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